Allspring Global Investments Holdings LLC Sells 290 Shares of The Cooper Companies, Inc. (NASDAQ:COO)

Allspring Global Investments Holdings LLC decreased its holdings in shares of The Cooper Companies, Inc. (NASDAQ:COO) by 3.0% in the 4th quarter, Holdings Channel reports. The fund owned 9,493 shares of the medical device company’s stock after selling 290 shares during the period. Allspring Global Investments Holdings LLC’s holdings in Cooper Companies were worth $861,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. Ashton Thomas Securities LLC acquired a new position in shares of Cooper Companies in the third quarter valued at approximately $25,000. Covestor Ltd increased its position in Cooper Companies by 144.9% during the 3rd quarter. Covestor Ltd now owns 338 shares of the medical device company’s stock valued at $37,000 after purchasing an additional 200 shares during the period. Byrne Asset Management LLC acquired a new stake in shares of Cooper Companies during the 4th quarter worth approximately $33,000. Brown Brothers Harriman & Co. grew its position in shares of Cooper Companies by 191.0% during the 3rd quarter. Brown Brothers Harriman & Co. now owns 419 shares of the medical device company’s stock worth $46,000 after buying an additional 275 shares during the period. Finally, West Financial Advisors LLC bought a new position in shares of Cooper Companies in the 4th quarter worth $49,000. Institutional investors and hedge funds own 24.39% of the company’s stock.

Cooper Companies Stock Performance

NASDAQ COO opened at $88.48 on Monday. The Cooper Companies, Inc. has a 1-year low of $84.76 and a 1-year high of $112.38. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.91 and a quick ratio of 1.12. The stock has a market capitalization of $17.66 billion, a PE ratio of 45.37, a P/E/G ratio of 2.25 and a beta of 1.00. The business has a 50 day simple moving average of $92.94 and a two-hundred day simple moving average of $99.66.

Cooper Companies (NASDAQ:COO) last issued its earnings results on Thursday, December 5th. The medical device company reported $1.04 earnings per share for the quarter, beating analysts’ consensus estimates of $1.00 by $0.04. The business had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1.03 billion. Cooper Companies had a return on equity of 9.38% and a net margin of 10.07%. Cooper Companies’s revenue was up 9.8% on a year-over-year basis. During the same period in the previous year, the company posted $0.87 EPS. On average, research analysts predict that The Cooper Companies, Inc. will post 3.98 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on COO. Citigroup cut their target price on Cooper Companies from $116.00 to $115.00 and set a “buy” rating on the stock in a report on Friday, December 6th. Morgan Stanley lowered their target price on Cooper Companies from $104.00 to $102.00 and set an “equal weight” rating on the stock in a research note on Friday, December 6th. Wells Fargo & Company lifted their price objective on Cooper Companies from $115.00 to $118.00 and gave the stock an “overweight” rating in a report on Friday, December 6th. Needham & Company LLC reissued a “hold” rating on shares of Cooper Companies in a report on Friday, December 6th. Finally, StockNews.com lowered Cooper Companies from a “buy” rating to a “hold” rating in a report on Wednesday, December 11th. Three investment analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $117.00.

About Cooper Companies

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.